Up more than 14% in early trading! This pharmaceutical stock has earned enough eyeballs because of "ibuprofen"

【Pharmaceutical Network Pharmaceutical Stock Market】News on December 19, the pharmaceutical sector changed, from the perspective of individual stocks, Shisi Pharmaceutical Group earned enough eyeballs, and the stock rose more than 14%
in early trading.
As of 9:29 on the 19th, Shisi Pharmaceutical Group rose by 14.
82%, with a quotation of HK $4.
880, a turnover of 1.
464 million, and a turnover rate of 0.
01%.

On the news, Shijiazhuang Four Medicines Co.
, Ltd.
, a wholly-owned subsidiary of the group, signed a letter of
intent for cooperation with a domestic pharmaceutical company on December 17, 2022.
Accordingly, the entrusting party intends to entrust the company to produce ibuprofen sustained-release tablets and pediatric aminophen xanamine granules, with an annual output of 10-2.
5 billion tablets and 65 million bags
respectively.
According to the announcement, according to the reference table of commonly used drugs for home treatment released by the joint prevention and control mechanism of the State Council earlier, ibuprofen and p-acetaminophen were selected as commonly used drugs
for fever symptoms.
The company expects contract manufacturing to deliver breakthrough growth
to the business.
In addition, on December 12, Shisi Pharmaceutical Group released news that its products such as Arbidol and azithromycin were listed as domestic anti-epidemic household backup drugs
.
Recently, the relevant departments of Shanghai and Wuhan have formulated a list of four types of drugs "cough, antipyretic, antiviral, and antibiotic", with a total of 174 drugs
.
Among them, many products of Shisi Pharmaceutical Group have been included, including: antiviral drug Arbidol hydrochloride, antibacterial drug azithromycin, cefodinib, Chinese proprietary medicine silver yellow capsule, etc
.
Shisi Pharmaceutical Group said that at present, the demand for related products has soared and is in a state
of short supply.
Arbidol and azithromycin are expected to deliver breakthrough growth
for the Group's future.
It can be seen that this pharmaceutical stock has recently earned enough eyeballs mainly related
to "ibuprofen" and other hot drugs.
Recently, with the optimization of epidemic prevention policies, and drugs such as ibuprofen have been selected as commonly used drugs for home treatment, analgesic and antipyretic drugs have set off a rush to buy, and under the condition of short supply, concept stocks such as "ibuprofen" continue to be active, such as Xinhua Pharmaceutical, the head enterprise of domestic ibuprofen, which has gained 6 consecutive boards
.
The industry reminds that the current active concept is emotional hype and should not be too indulged
.
And relevant enterprises have fulfilled expectations, pay attention to short-term risks
.
Guohai Securities said that logically, it is not surprising that ordinary people will stock up on some commonly used drugs, but all parties are already calling on everyone to buy and prepare drugs rationally, and not blindly hoard medicines
.
Therefore, the relevant industrial chain may be expected to usher in a phased performance outbreak, but the performance sustainability is not strong, and the performance expectations have basically or even exceeded the level after
the big rise.
Therefore, although the antiviral concept still maintains a high degree of activity, it is still necessary to pay attention to risk control
in the short term.
According to the data, Shisi Pharmaceutical Group is a large-scale pharmaceutical enterprise
with the coordinated development of R&D and industrialization in multiple fields of the industrial chain such as innovative drugs, generic drugs, characteristic APIs, high-end preparations and pharmaceutical packaging materials.
Among them, in the field of high-end preparations, the company continued to attack, on October 20 this year submitted linezolid dry suspension 4 generic marketing application, it is reported that this is the company's fourth dry suspension reported this year, the company continues to increase the research and development
of high-end preparations.
According to the third quarter report of 2022, in the first three quarters of this year, the company's unaudited turnover increased by 24.
2% year-on-year, or about HK$4.
873 billion, and the profit attributable to unaudited shareholders increased by 65.
2% year-on-year, to about HK$
836 million.
Among them, the turnover of non-PVC soft bag intravenous infusion exceeded HK $1.
4 billion, the turnover of upright soft bag IV infusion exceeded HK $400 million, and the intravenous infusion of polypropylene plastic bottle exceeded HK $600 million, and these three main products all had double-digit growth; In addition, the turnover of APIs also exceeded HK$1 billion, with a growth rate of 198.
8%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.